AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions

Provides AIM with patent protection for manufacturing Ampligen until 2041

Read more at globenewswire.com